Flare Up, Symptom, Juvenile Idiopathic Arthritis
Conditions
Keywords
Calprotectin, Biomarkers
Brief summary
A prospective study is proposed to serially determine new biomarkers: Calprotectin and Serum Amyloid Protein, alongside 'conventional' biomarkers: CRP and ESR, to help evaluate their utility in routine clinical practice
Detailed description
Pediatric inflammatory rheumatic diseases are relatively uncommon, but they represent the largest group of chronic diseases in childhood/adolescence and the leading cause of disability among children in developed countries. Poor control of the inflammatory activity of any of the aforementioned diseases can lead to growth failure (issues with growth and maturation), alterations in quality of life and school schedule for the patients, limitations secondary to joint impairments (especially in the case of JIA), and in the long term, the development of acquired amyloidosis (AA), which is a complication of any uncontrolled inflammatory process and significantly increases the morbidity and mortality of affected patients.The prognosis of pediatric inflammatory rheumatic diseases depends on the proper control of inflammation as well as the management of the immunosuppressive drugs used for this purpose. Even today, clinicians face many uncertainties in assessing the inflammatory status of our patients. Therefore, a prospective study is proposed to serially measure new biomarkers-Calprotectin and Serum Amyloid Protein-alongside 'conventional' biomarkers-CRP and ESR-to help evaluate their utility in routine clinical practice
Interventions
DIAGNOSTIC_TESTCalprotectine
Determination of calprotectin and amyloid protein in the serum of patients
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Patients in follow-up in our Pediatric Rheumatology Unit, with the diagnoses of: Juvenile Idiopathic Arthritis, Connective Diseases or Autoinflammatory Diseases
Exclusion criteria
No
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Calprotectin in pediatric population with rheumatological inflammatory diseases | Months 3, 6, 9 and 12 | To assess the clinical usefulness ofserum Calprotectin in pediatric population with rheumatological inflammatory diseases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Amyloid Protein in pediatric population with rheumatological inflammatory diseases | Months 3, 6, 9 and 12 | To assess the clinical usefulness of Serum Amyloid Protein in pediatric population with rheumatological inflammatory diseasesSedimentation Rate and the Clinical Criterion. Describe the evolution over time of these markers. |
| Correlation biomarkers | 1 year | Describe the correlation of Serum calportectin and Serum Amyloid Protein with the C-Reactive Protein, the Globular |
Countries
Spain
Contacts
PRINCIPAL_INVESTIGATORBerta Magallares
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
Outcome results
None listed